Physician profile
David Cislowski
NPI 1619924917
$2,557.90
in general payments reported to CMS, 2019-2025
22 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,216 · 2021: $39.76 · 2022: $135 · 2023: $136 · 2024: $381 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Artivion, INC. | $381.00 | 2019 | |
| Medtronic, INC. | $324.47 | 2025 | Aurora Ev-Icd Mri Surescan, Symplicity G3, Micra |
| Novartis Pharmaceuticals Corporation | $271.80 | 2019-2024 | |
| Amgen INC. | $236.07 | 2019-2022 | |
| Lantheus Medical Imaging, INC. | $222.46 | 2019-2023 | Definity |
| Pfizer INC. | $187.54 | 2019-2025 | |
| Biotronik INC. | $127.51 | 2025 | Amvia Edge |
| Abiomed | $125.62 | 2025 | |
| Boston Scientific Corporation | $124.19 | 2024 | Watchman Flx |
| Edwards Lifesciences Corporation | $119.18 | 2019 | |
| Cvrx, INC. | $106.16 | 2024 | Barostim Neo System |
| Haemonetics Corporation | $87.04 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.48 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.89 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $23.12 | 2024 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $21.00 | 2021 | |
| Esperion Therapeutics, INC. | $20.13 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $18.95 | 2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $18.84 | 2024 | Farxiga |
| Lilly USA, LLC | $15.75 | 2025 | Zepbound |
| Novo Nordisk INC | $13.70 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cislowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.